The BCG treatment in the superficial bladder cancer is utilized since 1976. There are some animal experiences with BCG intraprostatic in dogs with prostatic cancer.
Goal: determine if insitu BCG vaccine increase the prostatic immunity in patients with prostatic cancer.
Material and method: Three patients with D stage prostatic cancer where injected with 0.3-0.5 mg of BCG vaccine in the prostate. An histological picture where made in the some place before and after the injection. A RT-PCR study was made for gamma Interferon and Interleukin-4.
Results: In two patients we observed gamma interferon expression (67%) respect the control, this produce an increase of the cytotoxic T lymphocytes, natural killer cells and macrophagos, that have antitumoral action. One patient increased the interleukin-4 that means production of T helper lymphocytes and B lymphocytes. There wasn't complications.
Conclusions: The BCG vaccine injected in prostatic tissue of patients with prostatic cancer, produces an increase of cytotoxic T lymphocytes and natural killer cells, with antitumoral action.